Skip to main content
SpringerLink
Log in

Pathologische Grundlagen und Anforderungen

  • Chapter
  • First Online:
Medikamentöse Tumortherapie von Kopf-Hals-Tumoren

  • 335 Accesses

Zusammenfassung

Das Kapitel „Pathologische Grundlagen und Anforderungen“ gibt einen Überblick über klinisch-epidemiologische, morphologische und molekulare Grundlagen der in diesem Buch behandelten Neoplasien – Plattenepithelkarzinome der Haut und Schleimhäute, Basalzellkarzinome, Merkelzellkarzinome, Karzinome der Speicheldrüsen, Melanome der Haut und Schleimhäute – und die sich daraus ableitende pathologische Diagnostik der jeweiligen Entitäten. Es werden Epidemiologie und Prognose der inkludierten Neoplasien beschrieben und die zugrundeliegende Tumorgenese dargestellt. Anschließend wird der Fokus auf diagnostische histomorphologische Merkmale und ggf. für die Diagnostik erforderliche Zusatzuntersuchungen (Immunhistochemie, Molekularpathologie) gelegt – dies vor dem Hintergrund der aktuell gültigen Klassifikationen der Weltgesundheitsorganisation (WHO) und unter Einbezug aktueller Forschungsergebnisse. Ergänzt werden die Ausführungen durch eine Diskussion von gewebsbasierten Biomarkern, die für Tumoren der Kopf-Halsregion aufgrund ihrer prädiktiven oder prognostischen Aussagekraft relevant sind und deren Bestimmung im Rahmen von Companion Diagnostic-Tests bei der Anwendung bestimmter Medikamente obligat durchzuführen ist.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Weichert W, Ihrler S, Boxberg M et al (2018) [Morphology of non cutaneous head and neck squamous cell carcinoma]. Pathologe 39:3–10

    Google Scholar 

  2. Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29

    Article  Google Scholar 

  3. Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386

    Article  CAS  Google Scholar 

  4. El-Naggar AK (2017) WHO classification of head and neck toumours. International Agency for Research on Cancer, Lyon

    Google Scholar 

  5. Marur S, Forastiere AA (2008) Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83:489–501

    Article  Google Scholar 

  6. Gregoire V, Lefebvre JL, Licitra L et al (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v184–v186

    Article  Google Scholar 

  7. Barnes L, Eveson JW, Reichart P et al (2005) Pathology and genetics of head and neck tumours. IARC Press, cop, Lyon

    Google Scholar 

  8. Marur S, Forastiere AA (2016) Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc 91:386–396

    Article  Google Scholar 

  9. Pezzuto F, Buonaguro L, Caponigro F et al (2015) Update on head and neck cancer: current knowledge on epidemiology, risk factors, molecular features and novel therapies. Oncology 89:125–136

    Article  Google Scholar 

  10. Mortality GBD (2016) Causes of Death C: global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1459–1544

    Article  Google Scholar 

  11. Kaatsch P, Spix C, Katalinic A et al (2019) Gesellschaft der Epidemiologischen Krebsregister in Deutschland eV: Krebs in Deutschland 2015/16. Robert-Koch-Institut, Berlin

    Google Scholar 

  12. Gale N, Michaels L, Luzar B et al (2009) Current review on squamous intraepithelial lesions of the larynx. Histopathology 54:639–656

    Article  Google Scholar 

  13. WHO (2017) Classification of head and neck tumors, 4. Aufl. WHO Press, Lyon

    Google Scholar 

  14. van Hulst AM, Kroon W, van der Linden ES et al (2016) Grade of dysplasia and malignant transformation in adults with premalignant laryngeal lesions. Head Neck 38(Suppl 1):E2284–E2290

    Article  Google Scholar 

  15. Spielmann PM, Palmer T, McClymont L (2010) 15-Year review of laryngeal and oral dysplasias and progression to invasive carcinoma. Eur Arch Otorhinolaryngol 267:423–427

    Article  Google Scholar 

  16. Woo SB (2019) Oral epithelial dysplasia and premalignancy. Head Neck Pathol 13:423–439

    Article  Google Scholar 

  17. Iocca O, Sollecito TP, Alawi F et al (2020) Potentially malignant disorders of the oral cavity and oral dysplasia: a systematic review and meta-analysis of malignant transformation rate by subtype. Head Neck 42:539–555

    Article  Google Scholar 

  18. You EL, Henry M, Zeitouni AG (2019) Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management. Curr Oncol 26:119–123

    Article  CAS  Google Scholar 

  19. Kang H, Kiess A, Chung CH (2015) Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol 12:11–26

    Article  Google Scholar 

  20. Holmes BJ, Wenig BM (2019) Virus-associated carcinomas of the head & neck: update from the 2017 WHO classification. Ann Diagn Pathol 38:29–42

    Article  Google Scholar 

  21. Andreasen S, Kiss K, Mikkelsen LH et al (2019) An update on head and neck cancer: new entities and their histopathology, molecular background, treatment, and outcome. APMIS 127:240–264

    Article  Google Scholar 

  22. Seiwert TY (2014) Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing. J Clin Oncol 32:3914–3916

    Article  Google Scholar 

  23. O’Sullivan B, Huang SH, Su J et al (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 17:440–451

    Article  Google Scholar 

  24. Pytynia KB, Dahlstrom KR, Sturgis EM (2014) Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol 50:380–386

    Article  Google Scholar 

  25. Kim KY, Le QT, Yom SS et al (2017) Current state of PCR-based epstein-barr virus DNA testing for nasopharyngeal cancer. J Natl Cancer Inst 109(4):djx007

    Google Scholar 

  26. Boxberg M, Jesinghaus M, Dorfner C et al (2017) Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system. Histopathology 70:1125–1137

    Article  Google Scholar 

  27. Broders A (1920) Squamous cell epithelioma of the lip: a study of 537 cases. JAMA 74:689

    Google Scholar 

  28. Oc P, Pillai G, Patel S et al (2003) Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral Oncol 39:386–390

    Article  Google Scholar 

  29. Sawazaki-Calone I, Rangel A, Bueno AG et al (2015) The prognostic value of histopathological grading systems in oral squamous cell carcinomas. Oral Dis 21:755–761

    Article  CAS  Google Scholar 

  30. Weijers M, Snow GB, Bezemer PD et al (2009) Malignancy grading is no better than conventional histopathological grading in small squamous cell carcinoma of tongue and floor of mouth: retrospective study in 128 patients. J Oral Pathol Med 38:343–347

    Article  CAS  Google Scholar 

  31. Woolgar JA (2006) Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. Oral Oncol 42:229–239

    Article  Google Scholar 

  32. Bryne M, Koppang HS, Lilleng R et al (1992) Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 166:375–381

    Article  CAS  Google Scholar 

  33. Po Wing Yuen A, Lam KY, Lam LK et al (2002) Prognostic factors of clinically stage I and II oral tongue carcinoma-A comparative study of stage, thickness, shape, growth pattern, invasive front malignancy grading, Martinez-Gimeno score, and pathologic features. Head Neck 24:513–520

    Article  Google Scholar 

  34. Bhargava A, Saigal S, Chalishazar M (2010) Histopathological grading systems in oral squamous cell carcinoma: a review. J Int Oral Health 2:1–10

    Google Scholar 

  35. Anneroth G, Batsakis J, Luna M (1987) Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Scand J Dent Res 95:229–249

    CAS  Google Scholar 

  36. Anneroth G, Batsakis J, Luna M (1987) Review of the literature and a recommended system of malignancy grading in oral squamous cell carcinomas. Eur J Oral Sci 95:229–249

    Article  CAS  Google Scholar 

  37. Almangush A, Pirinen M, Heikkinen I et al (2018) Tumour budding in oral squamous cell carcinoma: a meta-analysis. Br J Cancer 118:577–586

    Article  Google Scholar 

  38. Zhu Y, Liu H, Xie N et al (2018) Impact of tumor budding in head and neck squamous cell carcinoma: a meta-analysis. Head Neck 41(2):542–550

    Google Scholar 

  39. Boxberg M, Bollwein C, Johrens K et al (2019) Novel prognostic histopathological grading system in oral squamous cell carcinoma based on tumour budding and cell nest size shows high interobserver and intraobserver concordance. J Clin Pathol 72:285–294

    Article  Google Scholar 

  40. Boxberg M, Kuhn PH, Reiser M et al (2019) Tumor budding and cell nest size are highly prognostic in laryngeal and hypopharyngeal squamous cell carcinoma: further evidence for a unified histopathologic grading system for squamous cell carcinomas of the upper aerodigestive tract. Am J Surg Pathol 43:303–313

    Article  Google Scholar 

  41. Jesinghaus M, Steiger K, Stogbauer F et al (2020) Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. Br J Cancer 122(6):835–846

    Google Scholar 

  42. Weichert W, Kossakowski C, Harms A et al (2016) Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma. Eur Respir J 47:938–946

    Article  CAS  Google Scholar 

  43. Ueno H, Ishiguro M, Nakatani E et al (2019) Prospective multicenter study on the prognostic and predictive impact of tumor budding in stage II colon cancer: results from the SACURA trial. J Clin Oncol 37:1886–1894

    Article  CAS  Google Scholar 

  44. Oh BY, Park YA, Huh JW et al (2018) Prognostic impact of tumor-budding grade in stages 1–3 colon cancer: a retrospective cohort study. Ann Surg Oncol 25:204–211

    Article  Google Scholar 

  45. Zlobec I, Hadrich M, Dawson H et al (2014) Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br J Cancer 110:1008–1013

    Article  CAS  Google Scholar 

  46. Onkologie L (2019) S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021/007OL

    Google Scholar 

  47. Chernock RD, El-Mofty SK, Thorstad WL et al (2009) HPV-related nonkeratinizing squamous cell carcinoma of the oropharynx: utility of microscopic features in predicting patient outcome. Head Neck Pathol 3:186–194

    Article  Google Scholar 

  48. WITTEKIND C (2016) TNM: Klassifikation maligner Tumoren. John Wiley & Sons

    Google Scholar 

  49. Reck M, Rodriguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50 % or greater. J Clin Oncol 37:537–546

    Article  CAS  Google Scholar 

  50. Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550

    Article  CAS  Google Scholar 

  51. Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4:e180013

    Article  Google Scholar 

  52. Chow LQM, Haddad R, Gupta S et al (2016) Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 34:3838–3845

    Article  CAS  Google Scholar 

  53. Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909–1920

    Article  CAS  Google Scholar 

  54. Bishop JA, Ma XJ, Wang H et al (2012) Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol 36:1874–1882

    Article  Google Scholar 

  55. Stransky N, Egloff AM, Tward AD et al (2011) The mutational landscape of head and neck squamous cell carcinoma. Science 333:1157–1160

    Article  CAS  Google Scholar 

  56. Seiwert TY, Zuo Z, Keck MK et al (2015) Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res 21:632–641

    Article  CAS  Google Scholar 

  57. Cancer Genome Atlas N (2015) Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517:576–582

    Article  Google Scholar 

  58. Chung CH, Parker JS, Karaca G et al (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5:489–500

    Article  CAS  Google Scholar 

  59. Walter V, Yin X, Wilkerson MD et al (2013) Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One 8:e56823

    Article  CAS  Google Scholar 

  60. Keck MK, Zuo Z, Khattri A et al (2015) Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res 21:870–881

    Article  CAS  Google Scholar 

  61. Tonella L, Giannoccaro M, Alfieri S et al (2017) Gene expression signatures for head and neck cancer patient stratification: are results ready for clinical application? Curr Treat Options in Oncol 18:32

    Article  Google Scholar 

  62. Hanna GJ, Lizotte P, Cavanaugh M et al (2018) Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight 3:98811

    Article  Google Scholar 

  63. Son E, Panwar A, Mosher CH et al (2018) Cancers of the major salivary gland. J Oncol Pract 14:99–108

    Article  Google Scholar 

  64. Lassche G, van Boxtel W, Ligtenberg MJL et al (2019) Advances and challenges in precision medicine in salivary gland cancer. Cancer Treat Rev 80:101906

    Article  CAS  Google Scholar 

  65. Ali S, Bryant R, Palmer FL et al (2015) Distant metastases in patients with carcinoma of the major salivary glands. Ann Surg Oncol 22:4014–4019

    Article  Google Scholar 

  66. Nam SJ, Roh JL, Cho KJ et al (2016) Risk factors and survival associated with distant metastasis in patients with carcinoma of the salivary gland. Ann Surg Oncol 23:4376–4383

    Article  Google Scholar 

  67. Skálová A, Stenman G, Simpson RH et al (2018) The role of molecular testing in the differential diagnosis of salivary gland carcinomas. Am J Surg Pathol 42:e11–e27

    Article  Google Scholar 

  68. Nagao T (2013) „Dedifferentiation“ and high-grade transformation in salivary gland carcinomas. Head Neck Pathol 7(Suppl 1):S37–S47

    Article  Google Scholar 

  69. Skalova A, Gnepp DR, Lewis JS Jr et al (2017) Newly described entities in salivary gland pathology. Am J Surg Pathol 41:e33–e47

    Article  Google Scholar 

  70. Di Palma S (2013) Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesions. Head Neck Pathol 7(Suppl 1):S68–S76

    Article  Google Scholar 

  71. Haller F, Skalova A, Ihrler S et al (2019) Nuclear NR4A3 immunostaining is a specific and sensitive novel marker for acinic cell carcinoma of the salivary glands. Am J Surg Pathol 43:1264–1272

    Article  Google Scholar 

  72. Haller F, Bieg M, Will R et al (2019) Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands. Nat Commun 10:368

    Article  CAS  Google Scholar 

  73. Hong DS, DuBois SG, Kummar S et al (2020) Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21(4):531–540

    Google Scholar 

  74. Doebele RC, Drilon A, Paz-Ares L et al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 21:271–282

    Article  CAS  Google Scholar 

  75. Leiter U, Eigentler T, Garbe C (2014) Epidemiology of skin cancer. Adv Exp Med Biol 810:120–140

    Google Scholar 

  76. Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27:3–9

    Article  Google Scholar 

  77. Elder DE, Massi D, Scolyer RA et al (2018) WHO classification of skin tumours. International Agency for Research on Cancer, Lyon

    Google Scholar 

  78. Homsi J, Kashani-Sabet M, Messina JL et al (2005) Cutaneous melanoma: prognostic factors. Cancer Control 12:223–229

    Article  Google Scholar 

  79. Hayward NK, Wilmott JS, Waddell N et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545:175–180

    Article  CAS  Google Scholar 

  80. Gospodarowicz MK, Brierley JD, Wittekind C (2017) TNM classification of malignant tumours. Wiley, Oxford

    Google Scholar 

  81. Ascierto PA, Accorona R, Botti G et al (2017) Mucosal melanoma of the head and neck. Crit Rev Oncol Hematol 112:136–152

    Article  Google Scholar 

  82. McLaughlin CC, Wu XC, Jemal A et al (2005) Incidence of noncutaneous melanomas in the U.S. Cancer 103:1000–1007

    Article  Google Scholar 

  83. Elder DE, Bastian BC, Cree IA et al (2020) The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 144(4):500–522

    Google Scholar 

  84. Schadendorf D, van Akkooi ACJ, Berking C et al (2018) Melanoma. Lancet 392:971–984

    Article  Google Scholar 

  85. Ferrara G, Senetta R, Paglierani M et al (2012) Main clues in the pathologic diagnosis of melanoma: is molecular genetics helping? Dermatol Ther 25:423–431

    Article  Google Scholar 

  86. Zembowicz A, Mihm MC (2004) Dermal dendritic melanocytic proliferations: an update. Histopathology 45:433–451

    Article  CAS  Google Scholar 

  87. Weyers W, Diaz C, Weyers I et al (1999) [The skin biopsy]. Hautarzt 50:145–158

    Google Scholar 

  88. Pfohler C, Vogt T, Muller CS (2015) [Malignant head and neck melanoma: part 1: diagnosis and histological particularities]. HNO 63:523–534; quiz 535–536

    Google Scholar 

  89. Que SKT, Zwald FO, Schmults CD (2018) Cutaneous squamous cell carcinoma: Incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol 78:237–247

    Article  Google Scholar 

  90. Waldman A, Schmults C (2019) Cutaneous squamous cell carcinoma. Hematol Oncol Clin North Am 33:1–12

    Article  Google Scholar 

  91. Nehal KS, Bichakjian CK (2018) Update on keratinocyte carcinomas. N Engl J Med 379:363–374

    Article  CAS  Google Scholar 

  92. Keohane SG, Proby CM, Newlands C et al (2018) The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K. Br J Dermatol 179:824–828

    Article  CAS  Google Scholar 

  93. Majores M, Bierhoff E (2015) [Actinic keratosis, Bowen’s disease, keratoacanthoma and squamous cell carcinoma of the skin]. Pathologe 36:16–29

    Google Scholar 

  94. Cassarino DS, Derienzo DP, Barr RJ (2006) Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification – part two. J Cutan Pathol 33:261–279

    Article  Google Scholar 

  95. Cassarino DS, Derienzo DP, Barr RJ (2006) Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one. J Cutan Pathol 33:191–206

    Google Scholar 

  96. Chan TA, Yarchoan M, Jaffee E et al (2019) Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol 30:44–56

    Article  CAS  Google Scholar 

  97. Cameron MC, Lee E, Hibler BP et al (2019) Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations. J Am Acad Dermatol 80:303–317

    Article  Google Scholar 

  98. Frerich B, Prall F (2018) [Basal cell carcinoma of the face and scalp: an update on treatment options]. Pathologe 39:457–472

    Google Scholar 

  99. Bichakjian CK, Olencki T, Aasi SZ et al (2016) Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 14:574–597

    Article  Google Scholar 

  100. Lang BM, Balermpas P, Bauer A et al (2019) S2k-Leitlinie Basalzellkarzinom der Haut–Teil 1: Epidemiologie, Genetik und Diagnostik. JDDG J Dtsch Dermatol Ges 17:94–104

    Google Scholar 

  101. Emge DA, Cardones AR (2019) Updates on Merkel cell carcinoma. Dermatol Clin 37:489–503

    Article  CAS  Google Scholar 

  102. Robinson CG, Tan D, Yu SS (2019) Recent advances in Merkel cell carcinoma. F1000Res 8:1995

    Article  CAS  Google Scholar 

  103. Tetzlaff MT, Harms PW (2020) Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma. Mod Pathol 33:42–55

    Article  Google Scholar 

  104. Coggshall K, Tello TL, North JP et al (2018) Merkel cell carcinoma: an update and review: pathogenesis, diagnosis, and staging. J Am Acad Dermatol 78:433–442

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Technische Universität München, München, Deutschland

    Melanie Boxberg & Wilko Weichert

  2. Pathologie München-Nord, München, Deutschland

    Melanie Boxberg

Authors
  1. Melanie Boxberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wilko Weichert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Melanie Boxberg .

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie, Universitätsklinikum Würzburg, Würzburg, Deutschland

    Urs Müller-Richter

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Boxberg, M., Weichert, W. (2022). Pathologische Grundlagen und Anforderungen. In: Müller-Richter, U. (eds) Medikamentöse Tumortherapie von Kopf-Hals-Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62808-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62808-9_2

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62807-2

  • Online ISBN: 978-3-662-62808-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation